Algernon Pharmaceuticals (CSE:AGN) achieves co-primary endpoint in its Phase 2 study of Ifenprodil
Algernon Pharmaceuticals (AGN) has met the co-primary endpoint in its Phase 2 proof of concept study evaluating NP-120 (Ifenprodil). Ifenprodil is being evaluated for the potential treatment of idiopathic pulmonary fibrosis (“IPF”) and chronic cough.
Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Sabrina Cuthbert to discuss the update in this exclusive Market Herald Canada interview.
Weekly Update – Top Cannabis News Stories
1 | Top Story: Tilray Brands Inc. (TSX:TLRY) launches cannabis education platform.
2 | Avicanna Inc. (TSX:AVCN) and Ei. Ventures enter into agreement to develop and commercialize adaptogen nutraceuticals.
3 | Partnership update from Red Light Holland Corp. (CSE:TRIP).
4 | Ignite International Brands Ltd. (CSE:BILZ) announces proposed going private transaction.
5 | Field Trip Health Ltd. (TSX:FTRP) announces first dosings in Phase 1 clinical study of FT-104.
Top Cannabis Stocks July 14 to July 20, 2022
1. T.WEED | 16,627 views | Canopy Growth Corp.
2. TLRY |10,848 views | Tilray Brands Inc.
3. T.HEXO | 9,795 views | HEXO Corp.
4. C.TNY | 5,324 views | Tinley Beverage Co Inc.
5. T.OGI | 2,474 views | OrganiGram Inc.
6. C.CURA | 2,342 views | Curaleaf Holdings Inc.